v3.26.1
Segment Information - Schedule of Reportable Segments (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting [Line Items]            
Sales         $ 4,942,633 $ 4,597,730
Cost of sales         (3,236,047) (3,496,817)
Operating Expenses            
Research and development $ 1,022,630 $ 425,370 $ 2,222,732 $ 2,243,948 2,853,920 3,217,517
General and administrative 1,742,016 1,584,393 4,304,323 4,155,493 6,557,822 5,798,226
Amortization and depreciation 51,707 51,706 156,912 158,289 212,839 219,600
Foreign exchange loss (gain) 23,168 22,165 62,026 50,608 28,471 61,921
Total operating expenses 2,839,521 2,083,634 6,745,993 6,608,338 9,653,052 9,297,264
Other Income (Expense)            
Interest and other income 47,770 16,565 215,914 104,195    
Finance expense (351,549) (371,549)
Net loss from continuing operations before taxes (2,791,751) (2,067,069) (6,530,079) (6,855,692) (8,162,133) (7,668,450)
Income tax expense 7,100
Net loss from continuing operations $ (2,791,751) $ (2,067,069) $ (6,530,079) $ (6,855,692)    
Reportable segments [Member]            
Segment Reporting [Line Items]            
Sales         4,942,633 4,597,730
Cost of sales         (3,236,047) (3,496,817)
Finance Expense         (371,549)
Unrestricted cash         11,075,871 6,571,610
Operating Expenses            
Total operating expenses         (9,653,052) (9,297,264)
Other Income (Expense)            
Interest and other income         155,882 527,901
Net loss from continuing operations before taxes         (8,162,133) (7,668,450)
InMed [Member] | Reportable segments [Member]            
Segment Reporting [Line Items]            
Sales        
Cost of sales        
Finance Expense         (371,549)
Unrestricted cash         10,684,376 5,669,113
Operating Expenses            
Total operating expenses         (8,474,641) (8,400,411)
Other Income (Expense)            
Interest and other income         155,882 532,782
Net loss from continuing operations before taxes         (8,690,308) (7,867,629)
BayMedica [Member] | Reportable segments [Member]            
Segment Reporting [Line Items]            
Sales         4,942,633 4,597,730
Cost of sales         (3,236,047) (3,496,817)
Finance Expense        
Unrestricted cash         391,495 902,497
Operating Expenses            
Total operating expenses         (1,178,411) (896,853)
Other Income (Expense)            
Interest and other income         (4,881)
Net loss from continuing operations before taxes         $ 528,175 $ 199,179